U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07227779) titled 'B-PaLMZ for TB Meningitis' on Nov. 11.
Brief Summary: This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Study Start Date: Feb. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Tuberculous Meningitis
Intervention:
DRUG: BPaLMZ Regimen
bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Minnesota
Published by HT Digital Content Services with permission from Health Daily Digest....